Ongoing Clinical Studies

Rapamycin & Exercise

Rapamycin is the golden discovery from the Interventions Testing Program, where it extended both male and female mice lifespan by ~20%. It’s high time that we take this promising preclinical data and trial it in humans.

Due to how Rapamycin works, we think that it will improve the muscle performance of older adults when combined with exercise. If this proves to be true, we can help to make sure that older adults have the strength to continue doing the activities that they want to do and reduce the need for rest homes and private hospitals.

Overall, we want to explore the hypothesis that if we have periods of time where the mechanistic target of Rapamycin (mTOR) pathway is activated via exercise, combined with alternate periods of time where mTOR is inhibited using Sirolimus (Rapamycin), will result in greater muscle performance in older adults compared with just exercise alone.

If this study is successful, it will have profound implications. We may have a viable method for older adults to hold onto their muscle bulk and strength, thus significantly reducing the need for rest homes and private hospitals.

To do this, we propose a 13-week, randomized, double-blind, placebo-controlled, Phase 2a Proof of concept trial of 40 participants, with 20 in the placebo arm and 20 in the Sirolimus (Rapamycin) arm. Participants will complete a thrice-weekly at-home exercise program. Medication will be taken once a week. Before the trial begins, exercycles will be delivered to the participant’s house, and once the trial begins the participants will complete a standardized exercycle program.

This study is registered on the Australia New Zealand Clinical Trial Registry here under the registration number: ACTRN12622000480785p

We need to raise a total of $USD 492,177.69 and have raised $99,433.97 so far. 

Here’s a video explaining the study and fundraising so far: 

If you are in a position to donate, please consider doing so to help fund this trial and move the needle on human longevity